FDA approves newer, more effective anticoagulant drug Pradaxa
Boehringer Ingelheim s new anticoagulant drug Pradaxa was approved yesterday by the FDA to prevent blood clots in patients with atrial fibrillation. Compared to warfarin, an anticoagulant medication that has been in use since the 1950s, Pradaxa does not require frequent monitoring with blood tests. Further, it was more effective at preventing strokes the result of clots being embolized to the brain than the older drug in clinical trials.
